secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001193125-25-063235
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma raises ~$30M in underwritten and direct common stock offering at $13/share
--------------------------------------------------------------------------------

- Underwritten offering of 1,143,000 shares and 300,000 pre-funded warrants at $13.00/$12.9999 per unit.
- Concurrent registered direct offering of 900,000 shares to Averill funds (Suvretta affiliates) at same $13.00 price.
- Gross proceeds ~$30M; net proceeds to fund product candidate development, working capital, and general corporate purposes.
- Benitec discussed appointing David Friedman, managing director at Suvretta Capital, to the board, subject to approval.
- Offering expected to close March 26, 2025; underwriters include Leerink Partners and TD Cowen as bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525063235/0001193125-25-063235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525063235/d931233d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-063235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer